The Reality of M&A: Navigating the Emotional Vortex of Selling Your Practice
- 2 days ago
- 3 min read
"Here be dragons."
That used to be the warning old school cartographers wrote on maps to mark unexplored, dangerous territory. And honestly, it is the exact warning you need before stepping off the clinical floor and into the world of Mergers and Acquisitions (M&A).
We recently sat down with M&A expert Dan King on The Claim Game podcast to talk about what it actually takes to scale and sell a therapy practice. A lot of private practice owners enter a valuation thinking it is just a simple math equation or a corporate IQ test for their life’s work. You add up your revenue, subtract your overhead, apply a standard EBITDA multiplier, and you get a number.
But any M&A process is an absolute emotional vortex. It will test your boundaries, your patience, and your triggers in ways you never saw coming.
The Myth of the Purely Mathematical Deal
When you have spent a significant percentage of your career building a practice, treating patients, and managing a team, that business isn't just an asset. It is a piece of your identity.
When an investor looks at your numbers and values the practice lower than you feel it should be, it hurts. It feels like a direct attack on your pride. Even when the math is objective, the transaction itself never is. Every deal has its own unique, emotionally intense flavor, and because the financial and personal stakes are so high, people can easily end up triggering each other during negotiations.
Why the Truth Always Pops Out When Selling Your Practice
During the M&A process, buyers and sellers are locked in a strange, intimate dance. You can hide your operational quirks, your compliance flaws, or your personality triggers for one meeting. You cannot hide them during months of grueling due diligence.
As the saying goes, the truth always comes out in the wash. If the personal alignment isn't right, or if the parties lose their tempers, the deal will and probably should collapse.
The "Second Bite at the Apple"
However, if you build a true partnership based on alignment and shared culture, the payoff can be massive. Most modern transactions involve keeping the operator or founder in place with an ambitious growth trajectory.
Investors call this the "Second Bite at the Apple."
The First Bite: An investor buys a majority stake of your practice, giving you a life changing initial payout.
The Growth Phase: You partner with them to optimize operations, clear administrative bottlenecks, and maybe add synergistic services like psychiatry.
The Second Bite: Roughly five years later, you resell a pie that is significantly larger, resulting in a second payout that can be even juicier than the first.
How to Prepare Operationally (Before the Microscope)
If you want to survive the M&A vortex and protect your valuation, you can't have surprises waiting under the hood. Due diligence is essentially an operational proctology exam, and there is simply no kinder way to put it.
Investors are going to look closely at your clinician retention, because if your providers leave, the patients follow, and the revenue evaporates. They are also going to scrutinize your payer concentration. If 70% of your business relies on a single, volatile insurance company, that payer concentration is the double kiss of death for your valuation.
If you try to hide administrative messiness, uneven copay collections, or billing errors, it will ruin the transaction. The move is to get your processes entirely clean before you ever sit down at the negotiation table.
Ready to Find Your Bottlenecks?
Whether you are dreaming of a major exit five years from now or you just want to take absolute control of your current cash flow, you need a clear, objective baseline of your practice health.
We can help with that. Before you ever let an investor put your practice under a microscope, let our team run a Practice Health Check. We will take your practice's vitals, audit your billing workflows, and identify the hidden operational bottlenecks that could slash your valuation later.
